Q2 EPS Estimates for AngioDynamics Lifted by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Equities research analysts at Zacks Research lifted their Q2 2026 EPS estimates for shares of AngioDynamics in a report issued on Thursday, March 6th. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.11). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at ($0.17) EPS.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. During the same quarter last year, the firm posted ($0.05) EPS. The company’s quarterly revenue was down .1% on a year-over-year basis.

Separately, HC Wainwright raised their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Price Performance

Shares of ANGO opened at $9.10 on Monday. The firm has a 50-day moving average of $10.83 and a 200-day moving average of $8.59. AngioDynamics has a one year low of $5.26 and a one year high of $13.50. The company has a market cap of $368.24 million, a PE ratio of -1.62 and a beta of 0.56.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.40% of the stock is currently owned by corporate insiders.

Institutional Trading of AngioDynamics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in AngioDynamics by 4.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,968 shares of the medical instruments supplier’s stock worth $201,000 after purchasing an additional 969 shares in the last quarter. Rhumbline Advisers raised its stake in AngioDynamics by 1.7% in the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock worth $554,000 after purchasing an additional 1,021 shares in the last quarter. Invesco Ltd. raised its stake in AngioDynamics by 1.2% in the 4th quarter. Invesco Ltd. now owns 119,249 shares of the medical instruments supplier’s stock worth $1,092,000 after purchasing an additional 1,451 shares in the last quarter. OneDigital Investment Advisors LLC raised its stake in AngioDynamics by 14.0% in the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier’s stock worth $111,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in AngioDynamics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier’s stock worth $3,014,000 after purchasing an additional 2,270 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.